Malaria Vaccine Revolution: Uganda Leads Largest Rollout, New Candidates Show Promise
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Malaria Vaccine Revolution: Uganda Leads Largest Rollout, New Candidates Show Promise
-
ナレーター：
-
著者：
このコンテンツについて
Uganda has made headlines by launching the largest malaria vaccine introduction to date. As of April 2025, the country has begun administering the R21/Matrix-M malaria vaccine, targeting 1.1 million children under the age of two. This vaccine, which is given in four doses at 6, 7, 8, and 18 months, is part of a broader initiative to integrate malaria vaccines into childhood immunization programs across Africa. Nineteen countries, including Uganda, Benin, Burkina Faso, and others, are already offering either the RTS,S or R21 malaria vaccines as part of their national malaria control plans, with more countries expected to follow suit in 2025[5].
The RTS,S and R21 vaccines, both prequalified by the World Health Organization (WHO) for safety and quality, have been rolled out extensively. The RTS,S vaccine was prequalified in July 2022, and the R21 vaccine received prequalification in December 2023. These vaccines target the pre-erythrocyte stage of the malaria parasite and have been instrumental in reducing malaria cases and fatalities in high-risk areas[5].
In addition to these established vaccines, new candidates are showing promising results. A blood-stage malaria vaccine candidate, RH5.1/Matrix-M, has demonstrated a 55% efficacy in preventing clinical malaria over six months in a phase 2b clinical trial. Unlike the RTS,S and R21 vaccines, RH5.1/Matrix-M targets the blood-stage of the parasite, offering a complementary approach to existing vaccines. This vaccine candidate has been well tolerated, with mild adverse events such as fever and injection site swelling, and has induced high concentrations of anti-RH5.1 serum IgG antibodies and in-vitro growth inhibition activity against Plasmodium falciparum[4].
However, not all malaria vaccine trials are proceeding without challenges. The U.S. Food and Drug Administration (FDA) has paused BioNTech's phase 1/2a trial of its experimental malaria vaccine, BNT165e, due to unspecified concerns. This pause highlights the rigorous regulatory scrutiny that new vaccine candidates must undergo to ensure safety and efficacy[2].
Despite these setbacks, research and development continue to advance. Recent collaborations between research partners have led to the advancement of two new malaria vaccine candidates, further expanding the arsenal against this debilitating disease[3].
As the demand for malaria vaccines remains high, with at least 30 African countries planning to introduce these vaccines into their immunization programs, the availability of multiple safe and effective vaccines is crucial. The ongoing efforts to ramp up production and introduce new vaccine candidates are pivotal in the global fight against malaria.